Literature DB >> 21574625

Structure-activity relationship studies to probe the phosphoprotein binding site on the carboxy terminal domains of the breast cancer susceptibility gene 1.

Ziyan Yuan1, Eric A Kumar, Smitha Kizhake, Amarnath Natarajan.   

Abstract

Carboxy terminal BRCT domains of the breast cancer susceptibility gene 1 (BRCA1) bind to phosphorylated proteins through a pSXXF consensus recognition motif. We report a systematic structure-activity relationship study that maps the BRCT(BRCA1)-pSXXF binding interface, leading to identification of peptides with nanomolar binding affinities comparable to those of the previously reported 13-mer peptides and providing a clear description of the pSXXF-BRCT interface, which is essential for developing small molecule inhibitors via the peptidomimetic approach.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21574625      PMCID: PMC3117075          DOI: 10.1021/jm1016413

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  23 in total

1.  Structural basis of BACH1 phosphopeptide recognition by BRCA1 tandem BRCT domains.

Authors:  Maria Victoria E Botuyan; Yves Nominé; Xiaochun Yu; Nenad Juranic; Slobodan Macura; Junjie Chen; Georges Mer
Journal:  Structure       Date:  2004-07       Impact factor: 5.006

Review 2.  Chemical genetics to chemical genomics: small molecules offer big insights.

Authors:  David R Spring
Journal:  Chem Soc Rev       Date:  2005-06       Impact factor: 54.564

3.  Thermodynamics of phosphopeptide tethering to BRCT: the structural minima for inhibitor design.

Authors:  G L Lokesh; B K Muralidhara; Surendra S Negi; Amarnath Natarajan
Journal:  J Am Chem Soc       Date:  2007-08-09       Impact factor: 15.419

4.  Poly-L-proline type II peptide mimics as probes of the active site occupancy requirements of cGMP-dependent protein kinase.

Authors:  R Zhang; C K Nickl; A Mamai; S Flemer; A Natarajan; W R Dostmann; J S Madalengoitia
Journal:  J Pept Res       Date:  2005-10

5.  High-throughput fluorescence polarization assay to identify small molecule inhibitors of BRCT domains of breast cancer gene 1.

Authors:  G L Lokesh; Aparna Rachamallu; G D Kishore Kumar; Amarnath Natarajan
Journal:  Anal Biochem       Date:  2006-02-03       Impact factor: 3.365

6.  Structural evidence for direct interactions between the BRCT domains of human BRCA1 and a phospho-peptide from human ACC1.

Authors:  Yang Shen; Liang Tong
Journal:  Biochemistry       Date:  2008-05-02       Impact factor: 3.162

7.  Dual-fluorophore quantitative high-throughput screen for inhibitors of BRCT-phosphoprotein interaction.

Authors:  Anton Simeonov; Adam Yasgar; Ajit Jadhav; G L Lokesh; Carleen Klumpp; Sam Michael; Christopher P Austin; Amarnath Natarajan; James Inglese
Journal:  Anal Biochem       Date:  2007-12-05       Impact factor: 3.365

8.  Structural basis of phosphopeptide recognition by the BRCT domain of BRCA1.

Authors:  R Scott Williams; Megan S Lee; D Duong Hau; J N Mark Glover
Journal:  Nat Struct Mol Biol       Date:  2004-05-09       Impact factor: 15.369

9.  Kinetic analysis of interaction of BRCA1 tandem breast cancer c-terminal domains with phosphorylated peptides reveals two binding conformations.

Authors:  Yves Nominé; Maria Victoria Botuyan; Zeljko Bajzer; Whyte G Owen; Ariel J Caride; Emeric Wasielewski; Georges Mer
Journal:  Biochemistry       Date:  2008-08-22       Impact factor: 3.162

Review 10.  Small-molecule inhibitors of protein-protein interactions.

Authors:  Thorsten Berg
Journal:  Curr Opin Drug Discov Devel       Date:  2008-09
View more
  11 in total

Review 1.  BRCA1-directed, enhanced and aberrant homologous recombination: mechanism and potential treatment strategies.

Authors:  Seth M Dever; E Railey White; Matthew C T Hartman; Kristoffer Valerie
Journal:  Cell Cycle       Date:  2012-02-15       Impact factor: 4.534

Review 2.  Small molecule adenosine 5'-monophosphate activated protein kinase (AMPK) modulators and human diseases.

Authors:  Sandeep Rana; Elizabeth C Blowers; Amarnath Natarajan
Journal:  J Med Chem       Date:  2014-08-28       Impact factor: 7.446

3.  Exploiting the P-1 pocket of BRCT domains toward a structure guided inhibitor design.

Authors:  Ziyan Yuan; Eric A Kumar; Stephen J Campbell; Nicholas Y Palermo; Smitha Kizhake; J N Mark Glover; Amarnath Natarajan
Journal:  ACS Med Chem Lett       Date:  2011-10-13       Impact factor: 4.345

4.  Irreversible binding of an anticancer compound (BI-94) to plasma proteins.

Authors:  Nagsen Gautam; Rhishikesh Thakare; Sandeep Rana; Amarnath Natarajan; Yazen Alnouti
Journal:  Xenobiotica       Date:  2015-04-14       Impact factor: 1.908

5.  Computational and experimental studies of the interaction between phospho-peptides and the C-terminal domain of BRCA1.

Authors:  Victor M Anisimov; Arturas Ziemys; Smitha Kizhake; Ziyan Yuan; Amarnath Natarajan; Claudio N Cavasotto
Journal:  J Comput Aided Mol Des       Date:  2011-11-16       Impact factor: 3.686

6.  Peptide library approach to uncover phosphomimetic inhibitors of the BRCA1 C-terminal domain.

Authors:  E Railey White; Luxin Sun; Zhong Ma; Jason M Beckta; Brittany A Danzig; David E Hacker; Melissa Huie; David C Williams; Ross A Edwards; Kristoffer Valerie; J N Mark Glover; Matthew C T Hartman
Journal:  ACS Chem Biol       Date:  2015-02-05       Impact factor: 5.100

7.  Synthesis of aminopyrazole analogs and their evaluation as CDK inhibitors for cancer therapy.

Authors:  Sandeep Rana; Yogesh A Sonawane; Margaret A Taylor; Smitha Kizhake; Muhammad Zahid; Amarnath Natarajan
Journal:  Bioorg Med Chem Lett       Date:  2018-10-15       Impact factor: 2.823

8.  Inhibition of BRCT(BRCA1)-phosphoprotein interaction enhances the cytotoxic effect of olaparib in breast cancer cells: a proof of concept study for synthetic lethal therapeutic option.

Authors:  Ziyan Yuan Pessetto; Ying Yan; Tadayoshi Bessho; Amarnath Natarajan
Journal:  Breast Cancer Res Treat       Date:  2012-05-06       Impact factor: 4.872

Review 9.  Phosphopeptide interactions with BRCA1 BRCT domains: More than just a motif.

Authors:  Qian Wu; Harry Jubb; Tom L Blundell
Journal:  Prog Biophys Mol Biol       Date:  2015-02-17       Impact factor: 3.667

10.  The paradox of conformational constraint in the design of Cbl(TKB)-binding peptides.

Authors:  Eric A Kumar; Qianyi Chen; Smitha Kizhake; Carol Kolar; Myungshim Kang; Chia-En A Chang; Gloria E O Borgstahl; Amarnath Natarajan
Journal:  Sci Rep       Date:  2013       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.